ArticleAlzheimer's research & therapy2016
Regional tau deposition measured by [
Article in Alzheimer's research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 55 citations in OpenAlex.
- The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- Association of dopamine depletion and cholinergic basal forebrain atrophy with brain metabolism and cognition in Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Neurometabolic topography and associations with cognition in Alzheimer's disease: A whole-brain high-resolution 3D MRSI study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease.Acta pharmaceutica Sinica. B · 2024Review
- The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease.Human brain mapping · 2023Article
- Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease.Alzheimer's research & therapy · 2022Article
- The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.Alzheimer's research & therapy · 2022Article
- Sodium selenate as a therapeutic for tauopathies: A hypothesis paper.Frontiers in aging neuroscience · 2022Article
- GC-CNNnet: Diagnosis of Alzheimer's Disease with PET Images Using Genetic and Convolutional Neural Network.Computational intelligence and neuroscience · 2022Article
- Lack of association between cortical amyloid deposition and glucose metabolism in early stage Alzheimer´s disease patients.Radiology and oncology · 2021Article
- Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer's continuum.Alzheimer's research & therapy · 2021Article
- [Molecular psychiatry · 2021Article
- Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2021Article
- Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020Article
- Characterization ofMolecules (Basel, Switzerland) · 2020Article
- PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape.Molecules (Basel, Switzerland) · 2020Review
- The A/T/N model applied through imaging biomarkers in a memory clinic.European journal of nuclear medicine and molecular imaging · 2020Article
- Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.Human brain mapping · 2019Review
- Tau PET imaging in neurodegenerative tauopathies-still a challenge.Molecular psychiatry · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent development of tau-specific positron emission tomography (PET) tracers has allowed in vivo quantification of regional tau deposition and offers the opportunity to monitor the progression of tau pathology along with cognitive impairment. In this study, we investigated the relationships of cerebral tau deposition ([
methodsNine patients diagnosed with AD dementia and 11 with prodromal AD (mild cognitive impairment, amyloid-positive on [
resultsSignificant negative associations were found between [
conclusionsThese findings suggest a mediating role for local glucose metabolism in the observed association between in vivo tau deposition and concomitant cognitive impairment in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.